Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Jaguar Animal Health ( (JAGX) ) has issued an announcement.
On September 9, 2025, Jaguar Health, Inc. entered into securities purchase agreements with certain investors to issue and sell approximately 951 shares of Series N Perpetual Preferred Stock for around $2.38 million in a private placement, which closed on September 10, 2025. The proceeds from this transaction are intended for working capital, general corporate purposes, and repayment of certain existing notes. The Series N Preferred Stock comes with specific rights and limitations, including no dividend entitlement, voting rights alongside common stock, and liquidation preferences. The company has also set covenants to maintain compliance with reporting requirements and trading conditions.
The most recent analyst rating on (JAGX) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Jaguar Animal Health stock, see the JAGX Stock Forecast page.
Spark’s Take on JAGX Stock
According to Spark, TipRanks’ AI Analyst, JAGX is a Neutral.
Jaguar Animal Health’s overall stock score is primarily impacted by its weak financial performance, characterized by high leverage and consistent losses. Technical indicators suggest a bearish trend, and valuation metrics are poor. While the earnings call provided some positive insights, they are overshadowed by ongoing financial challenges.
To see Spark’s full report on JAGX stock, click here.
More about Jaguar Animal Health
Average Trading Volume: 113,252
Technical Sentiment Signal: Sell
Current Market Cap: $4.5M
Find detailed analytics on JAGX stock on TipRanks’ Stock Analysis page.